ADC Therapeutics SAADC Therapeutics SAADC Therapeutics SA

ADC Therapeutics SA

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪193.38 M‬USD
−2.40USD
‪−240.05 M‬USD
‪69.56 M‬USD
‪77.58 M‬
Beta (1Y)
1.98
Employees (FY)
162
Change (1Y)
−155 −48.90%
Revenue / Employee (1Y)
‪429.37 K‬USD
Net income / Employee (1Y)
‪−1.48 M‬USD

About ADC Therapeutics SA


CEO
Ameet Mallik
Headquarters
Epalinges
Founded
2011
ISIN
CH0499880968
FIGI
BBG00Q6Q3QX1
ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ADCT is 2.13 USD — it has increased by 5.82% in the past 24 hours. Watch ADC Therapeutics SA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange ADC Therapeutics SA stocks are traded under the ticker ADCT.
ADCT stock has fallen by −39.39% compared to the previous week, the month change is a −25.93% fall, over the last year ADC Therapeutics SA has showed a 32.30% increase.
We've gathered analysts' opinions on ADC Therapeutics SA future price: according to them, ADCT price has a max estimate of 10.00 USD and a min estimate of 6.00 USD. Watch ADCT chart and read a more detailed ADC Therapeutics SA stock forecast: see what analysts think of ADC Therapeutics SA and suggest that you do with its stocks.
ADCT reached its all-time high on Jul 2, 2020 with the price of 56.59 USD, and its all-time low was 0.36 USD and was reached on Nov 13, 2023. View more price dynamics on ADCT chart.
See other stocks reaching their highest and lowest prices.
ADCT stock is 10.46% volatile and has beta coefficient of 1.98. Track ADC Therapeutics SA stock price on the chart and check out the list of the most volatile stocks — is ADC Therapeutics SA there?
Today ADC Therapeutics SA has the market capitalization of ‪193.38 M‬, it has increased by 15.63% over the last week.
Yes, you can track ADC Therapeutics SA financials in yearly and quarterly reports right on TradingView.
ADC Therapeutics SA is going to release the next earnings report on Mar 13, 2025. Keep track of upcoming events with our Earnings Calendar.
ADCT earnings for the last quarter are −0.42 USD per share, whereas the estimation was −0.40 USD resulting in a −6.33% surprise. The estimated earnings for the next quarter are −0.42 USD per share. See more details about ADC Therapeutics SA earnings.
ADC Therapeutics SA revenue for the last quarter amounts to ‪18.46 M‬ USD, despite the estimated figure of ‪18.43 M‬ USD. In the next quarter, revenue is expected to reach ‪18.85 M‬ USD.
ADCT net income for the last quarter is ‪−43.97 M‬ USD, while the quarter before that showed ‪−36.54 M‬ USD of net income which accounts for −20.32% change. Track more ADC Therapeutics SA financial stats to get the full picture.
No, ADCT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 18, 2024, the company has 162.00 employees. See our rating of the largest employees — is ADC Therapeutics SA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ADC Therapeutics SA EBITDA is ‪−133.07 M‬ USD, and current EBITDA margin is −231.62%. See more stats in ADC Therapeutics SA financial statements.
Like other stocks, ADCT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ADC Therapeutics SA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ADC Therapeutics SA technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ADC Therapeutics SA stock shows the sell signal. See more of ADC Therapeutics SA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.